Long-term exposure to estrogen and its metabolites may play an important role in renal cell carcinogenesis. Catechol-O-methyltransferase (COMT) participates in the estrogen metabolism pathway by neutralizing toxic substances. Although reduced COMT activity has been suggested to be a risk factor for estrogen-associated cancers, no studies have investigated the biological significance of COMT in the pathogenesis of human renal cell cancers (RCCs). We initially found that COMT levels are significantly decreased in human RCC tissues and cells suggesting it plays a suppressive role in tumor development. However, transient overexpression of COMT has no functional effect on RCC cell lines. In contrast, when cells overexpressing COMT are treated with its substrate 4-hydroxyestradiol (4-OHE 2 ), growth is inhibited by apoptotic cell death. We also found that COMT overexpression combined with 4-OHE 2 induces upregulation of growth arrest-and DNA damage-inducible protein a (GADD45a). We further show that downregulation of GADD45a by a small interfering RNA-mediated approach inhibits cell death, indicating the essential role of GADD45a in the underlying mechanism of COMT action in response to 4-OHE 2 . Finally, 4-methoxyestradiol fully reproduces the antiproliferative function of COMT with 4-OHE 2 by promoting GADD45a induction. Together, these findings show that COMT in the presence of 4-OHE 2 prevents RCC cell proliferation by enhancing apoptosis and that GADD45a plays a critical role in the COMT-mediated inhibition of RCC.
Introduction
In the USA, kidney cancer is among the 10 most common cancers in both men and women. It is estimated that 60 920 new cases and 13 120 deaths from the disease will occur in 2011 (1) . Renal cell cancer (RCC) is the most frequent type of kidney cancer and $80% of RCC are clear cell adenocarcinomas, the remainder being papillary ($15%), chromophobe ($5%) and collecting duct carcinomas (,1%) (2) . Genetic susceptibility, cigarette smoking, obesity, hypertension, chronic renal failure and occupational exposure to trichloroethylene have been considered as strong risk factors for RCC (1, 2) . There are almost twice as many RCC cases in men as in women, and men generally present with more severe malignancy, such as larger size, higher grade and higher stage of tumors than women. In addition, the mean age at diagnosis for men is slightly earlier and both overall and 5 years survival rate is also shorter than that of women (3, 4) . Although the reason for difference in rates of RCC between men and women remains unknown, there is substantial evidence suggesting that estrogen may be an additional etiological factor for RCC, especially in men. According to a report by Lipworth et al. (2) , the average age at RCC diagnosis is in the early 60s and men at this age have much higher levels of estrogen compared with postmenopausal women of similar age (5, 6) . Renal carcinoma has been found in male patients who had received long-term estrogen therapy for treating prostatic carcinoma (7, 8) . However, no association of RCC risk with estrogen replacement therapy in women was observed (9) . In the golden Syrian hamster, kidney tumors are normally produced only in males treated with synthetic estrogen and the induction of tumor can be blocked by the administration of estrogen antagonists (10, 11) .
In extrahepatic tissues including kidney, endogenous estrogens undergo oxidative metabolism catalyzed by cytochrome P450 1A1 and 1B1 to yield catechol estrogens, 2-hydroxyestradiol and 4-hydroxyestradiol (4-OHE 2 ), respectively. Of the two catechol estrogens, 4-OHE 2 is believed to be a critical intermediate in estrogen-induced cancers. It is further oxidized by metabolic redox cycling, and the resultant estradiol-3,4-quinones and reactive oxygen species have genotoxic and carcinogenic effects (12) . 4-OHE 2 is also capable of inducing cytotoxicity in human mammary epithelial cells and activation of nuclear factor-kappaB and extracellular signal-regulated kinase/mitogen-activated protein kinase pathways (13) .
Catechol-O-methyltransferase (COMT) is a phase II enzyme in the process of estrogen metabolism. It catalyzes O-methylation at either the 2-, 3-, 4-position of the catechol ring of a substrate and thus, methoxyestradiols (MEs) are produced from corresponding hydroxyestradiols (14) . It has been suggested that COMT may prevent the development of estrogen-associated cancers by this metabolic O-methylation of endogenous catechol estrogens. It reduces the level of 4-OHE 2 , thereby lowering the potential for genomic damage through DNA adduct formation or through oxygen radicals arising from quinone-semiquinone redox cycling of catechol estrogen (15, 16 ). 2-ME, which is produced from 2-OHE 2 has antiproliferative, antiangiogenic and proapoptotic activity in multiple types of cancer (17) . There is evidence for the protective role of COMT in estrogen-induced carcinogenesis. Administration of a COMT inhibitor, quercetin, increased the number of large renal tumors and the incidence of abdominal metastases in estradiol-treated hamsters (18, 19) . COMT also protects catechol estrogen-induced malignant transformation of human endometrial glandular cells by regulating oxidative stress (20) . Salama et al. (21) showed that 2-ME produced by COMT overexpression ameliorates estradiol-induced proliferation of human uterine leiomyoma cells by disturbing microtubule dynamics, inhibiting steroid receptor signaling and reducing HIF-1a and CYP19 expression.
The association of COMT polymorphisms with the risk of various cancers of the breast, endometrium, prostate, bladder, liver, stomach and esophagus has been investigated. Recently, we found that a COMT polymorphic variant, which may alter messenger RNA (mRNA) stability and/or translation efficiency, is significantly associated with risk for RCC in men (22) . Therefore in this study, we examined the expression level and functional significance of COMT in human RCC. Our results show that both the mRNA and protein levels of COMT are significantly decreased in RCC. Although overexpression alone has no obvious effect, COMT expression in the presence of 4-OHE 2 inhibits the proliferation of RCC cells, which results from increased apoptotic cell death. In addition, the critical role of 4-ME formation and subsequent growth arrest-and DNA damage-inducible protein a (GADD45a) induction as the underlying mechanism of COMT action were demonstrated.
Materials and methods

Cell lines and reagents
The immortalized human renal proximal tubule epithelial cell line, HK-2, renal cancer cell lines, Caki-1, ACHN and 769-P, and a prostate cancer cell line, LNCaP were obtained from the American Type Culture Collection (Manassas, VA). Keratinocyte serum-free medium, bovine pituitary extract and recombinant epidermal growth factor were purchased from Invitrogen (Carlsbad, CA). McCoy's 5A, Eagle's minimum essential medium with Eagle's balanced salts solution (EMEM), RPMI 1640, Opti-minimum essential medium and penicillin/streptomycin mixtures were obtained from the UCSF Cell Culture Facility. Phenol red-free McCoy's 5A and Eagle's minimum essential media were purchased from PromoCell (Heidelberg, Germany) and Invitrogen, respectively. Fetal bovine serum was a product of Atlanta Biologicals (Lawrenceville, GA). 4-OHE 2 and Ro 41-0960 were purchased from Sigma Chemical Co. (St Louis, MO). 4-ME was obtained from Steraloids (Newport, RI).
Cell culture
The HK-2 cell line was maintained in keratinocyte serum-free medium supplemented with 0.05 mg/ml bovine pituitary extract and 5 ng/ml recombinant epidermal growth factor. The Caki-1 and ACHN cell lines were grown in McCoy's 5A and Eagle's minimum essential medium, respectively. The 769-P and LNCaP cell lines were cultured in RPMI 1640 medium. All culture medium contained 10% fetal bovine serum and 100 lg/ml penicillin/streptomycin mixture. All cell lines were maintained at 37°C in a humidified atmosphere composed of 5% CO 2 /95% air.
Establishment of RCC cell lines stably expressing COMT Caki-1 and ACHN cells were transfected with pCMV6-ENTRY vector expressing the C-terminally Myc and Flag-tagged human membrane bound (MB)-COMT complementary DNA (cDNA) as well as empty pCMV6-EN-TRY vector as a control (OriGene Techologies, Rockville, MD) using Fugene HD Transfection Reagent (Roche Diagnostics, Indianapolis, IN) according to the manufacturer's protocol. Stable clones were selected with 500 lg/ml of G418 (Invitrogen). Colonies resistant to G418 appeared within 2 weeks, and single colonies were picked and then expanded for another 3 weeks to make the original stock cells.
Quantitative reverse transcription-polymerase chain reaction Total RNA from cultured cell lines was isolated using the RNeasy Mini Kit (Qiagen, Valencia, CA) and was converted into cDNA by using the iScript TM cDNA Synthesis Kit (Bio-Rad, Hercules, CA) according to the manufacturer's instruction. To assess gene expression, cDNAs were amplified with the TaqManÒ Gene Expression Assays and TaqManÒ Fast Universal polymerase chain reaction (PCR) Master Mix using the 7500 Fast Real-Time PCR System (Applied Biosystems, Foster City, CA). The target genes and their Assay ID were as follows: COMT (Hs00241349_m1) and GADD45a (Hs00169255_m1). Beta-actin was utilized to normalize COMT expression in normal and RCC clear cell tissues and glyceraldehyde-3-phosphate dehydrogenase was used as an internal control unless stated otherwise. The relative change in gene expression was calculated by the comparative Ct (threshold cycle) method using the 7500 Fast System Sequence Detection Software (Applied Biosystems). For COMT mRNA expression in normal and RCC clear cell tissues, TissueScan TM Kidney Cancer cDNA Arrays (OriGene Techologies) were subjected to quantitative polymerase chain reaction (Q-PCR) analysis. For investigation of gene expression profiling of selected apoptosis-related genes, the Human Apoptosis RT 2 Profiler PCR Array (SABiosciences, Frederick, MD) was used as per manufacturer's instructions. In brief, total RNA extracted from Caki-1/pCMV6 and Caki-1/COMT cells after 4-OHE 2 (50 lM) treatment for 48 h was converted into cDNA by using the RT 2 First Strand Kit. Q-PCR analysis was performed with RT 2 Real-Time TM SYBR Green/Rox PCR master mix. Gene expression levels were determined by using the data analyzer template provided by SABiosciences.
Western blot analysis
Whole-cell extracts were prepared using radioimmunoprecipitation assay buffer (Thermo Scientific, Rockford, IL) containing protease inhibitor cocktail (Roche Diagnostics). Total protein (40 lg) was loaded onto 12% Bis-Tris Gels with 3-(N-morpholino)propanesulfonic acid buffer and separated by a NuPAGE elecrophoresis system (Invitrogen). Protein was transferred to Invitrolon TM polyvinylidene difluoride and immunoblotting was carried out according to standard protocols. The antibodies used for immunoblotting were rabbit polyclonal antibody raised against COMT (Sigma-Aldrich, St Louis, MO) and GADD45a (Cell Signaling Technology, Danvers, MA), and mouse monoclonal antibody against GAPDH (Santa Cruz Biotechnology, Santa Cruz, CA) was used to confirm equal loading.
Immunohistochemistry
Immunostaining was performed on a formalin-fixed paraffin-embedded kidney cancer tissue array (US Biomax, Rockville, MD) using the ImmunoCruz Staining System (Santa Cruz Biotechnology). Briefly, the sections were deparaffinized in xylene and rehydrated in graded alcohols, followed by rinsing in dH 2 O. After antigen retrieval by microwaving, endogenous peroxidase activity was quenched with H 2 O 2 and rinsed with washing buffer. Normal goat serum was applied to minimize non-specific binding. The sections were incubated overnight at 4°C with rabbit polyclonal anti-COMT antibody (Sigma Life Sciences, St Louis, MO) diluted 1:250 in serum block followed by biotinylated anti-rabbit antibody. After incubation with horseradish peroxidase-streptavidin complex, Ultravision Plus DAB Plus Substrate System (Labvision, Fremont, CA) was added as chromogen followed by counterstaining with hematoxylin. Staining intensity of each tissue section was visually evaluated under an Olympus BX60 microscope equipped with Spot Advanced software (Diagnostic Instruments, Sterling Heights, MI) and was ranked on an overall scale from 0 to 3; with 0 indicating the absence of staining; 1, weak staining; 2, moderate staining and 3, strong staining. Assessment of the staining pattern was adapted and modified from the study of Fisher et al. (23) . In brief, the presence or absence of staining, depth of color and the number of cells showing a positive reaction were recorded. Dark cytoplasmic staining that is easily visible with a low power objective and involves .50% of cells was considered as strong, focal dark staining areas (,50% of cells) or moderate cytoplasmic staining of .50% of cells was classified as moderate and focal moderate staining in ,50% of cells or pale cytoplasmic staining in any proportion of cells not easily seen under a low power was categorized as weak.
Cell proliferation assay Cells were plated in triplicate in 96-well microplates at a density of 5 Â 10 3 cells per well in phenol red-free media supplemented with 10% charcoal-stripped fetal bovine serum (Invitrogen). The cells were then treated with 50 lM of either 4-OHE 2 or 4-ME. At the desired time point, the number of viable cells was determined by adding 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium-based CellTiter 96 AQueous One Solution Reagent (Promega, Madison, WI) to each well and measuring the absorbance at 490 nm on SPECTRA MAX 190 plate reader (Molecular Devices, Sunnyvale, CA). Results were expressed as the percentage of optical density, assuming that the absorbance of control cells was 100%. The working concentration of 4-OHE 2 and 4-ME was selected based on concentration-response studies (Supplementary Figure 1 is available at Carcinogenesis Online). In brief, cells were treated with 1, 10, 20, 50 and 100 lM of 4-OHE 2 or 2, 10, 20, 30 and 50 lM of 4-ME and cell proliferation was determined by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium assay. As a result, 50 lM was chosen for both since it showed the most significant growth inhibitory effect on cells. 
Apoptosis assay
Small interfering RNA transfection
When a cell density of 30-50% confluence was reached, small interfering RNA (siRNA) duplexes specific for human GADD45a or universal scrambled negative control (OriGene Techologies) was transfected using Lipofectamine 2000 Transfection Reagent (Invitrogen) as described by the manufacturer's instructions. Target specificity and knockdown efficiency were evaluated by both real-time PCR and western blotting with three different sets of siRNA duplexes at different concentrations. The siRNA duplex at a concentration of 20 nM showing the most efficient GADD45a knock down was selected and used for further experiments. Cells treated with Lipofectamine 2000 Transfection Reagent alone were included as a mock control for each experiment.
Statistical analysis
Values are presented as the mean ± standard error of mean based on results obtained from at least three independent experiments. Statistical significance COMT inhibits human RCC was evaluated by conducting a two-tailed unpaired Student's t-test using GraphPad PRISM Software.
Ã P , 0.05, ÃÃ P , 0.01, ÃÃÃ P , 0.001, n.s, non-significant.
Results
COMT expression is downregulated in RCC tissues and cell lines
Given that a polymorphic variant of COMT, with a potential to alter its expression, is a risk factor for RCC (22) , we initially examined whether COMT levels are changed in RCC tissues. Q-PCR studies showed significantly decreased expression of COMT mRNA in clear cell RCC compared with normal renal cells ( Figure 1A) . As previously reported (24) , immunohistochemical staining of COMT protein was predominantly observed in proximal convoluted tubules in the juxtamedullary cortex ( Figure 1B, left) . Although we are unable to distinguish COMT isoforms, most of the immunoreactive COMT was located in the cytoplasm, with only occasional cell nuclei showing positive staining in normal renal cells (Figure 1B, left) . In contrast, weak or no expression of COMT protein was observed in clear cell RCC tissues with average staining scores of 0.37 ± 0.16 (versus 2.63 ± 0.13 in normal tissues) ( Figure 1B, right) . The relative COMT expression levels in RCC cell lines were also compared with the immortalized kidney tubule epithelial cell line HK-2. Consistent with the observation in tissues, both COMT mRNA and protein levels were lower in RCC cell lines than in HK-2 cells ( Figure 1C and D, respectively). The COMT protein occurs as two distinct forms, in the cytoplasm as a soluble protein and in association with membranes, mainly in the rough endoplasmic reticulum as a membrane-bound form (25) . The human soluble (S)-COMT protein contains 221 amino acids and MB-COMT protein has 50 additional amino acids residues. Thus, their molecular weights are 25 and 30 kDa, respectively (25) . Although both forms of COMT are expressed in equal amounts in human kidney (25) , MB-COMT is predominantly expressed in both HK-2 and RCC cell lines ( Figure 1D ). These results showing lower COMT expression in cancer tissue and cells suggest that COMT may play a suppressive role in RCC tumorigenesis.
COMT overexpression enhances 4-OHE 2 -mediated growth inhibition of RCC cells Reduced expression of COMT in RCC tissues and cell lines led us to examine whether increased levels of COMT affects the growth of RCC. Since the majority of COMT is present as the MB form in RCC cell lines, we transiently transfected a plasmid containing human MB-COMT into Caki-1 cells, which has low level of endogenous COMT, and assessed the growth rate of the cells. However, there were no changes in proliferation, apoptosis and the cell cycle by transient upregulation of COMT in Caki-1 cells (data not shown).
Since COMT catalyzes the O-methylation of 2-or 4-OHE 2 and produces 2-or 4-ME, respectively (12) , it may affect the growth of RCC in the presence of its metabolic substrates. Indeed, production of 2-ME by COMT expression inhibits the 17b-estradiol-induced proliferation of human uterine leiomyoma cells (21) . However, a few studies have investigated the effect of 4-OHE 2 metabolism and 4-ME on cancer cell growth (26, 27) . Therefore, we explored the growth-inhibitory effect of 4-OHE 2 on COMT overexpressing RCC cells. To investigate this possibility, we first established Caki-1 and ACHN cell lines stably overexpressing MB-COMT. As shown in Figure 2A , a significant amount of exogenous protein was detected by western blotting in COMT-transfected RCC cell lines (Caki-1/ COMT and ACHN/COMT) but not in control vector-transfected cells (Caki-1/pCMV6 and ACHN/pCMV6). Next, we treated the stable COMT-expressing cell lines with 4-OHE 2 and examined cell proliferation. Overexpression of COMT significantly enhanced the level of growth inhibition that occurs in response to 4-OHE 2 in Ã P , 0.05, ÃÃ P , 0.01, ÃÃÃ P , 0.001.
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a time-dependent manner ( Figure 2B ). Pretreatment of cells with COMT-specific inhibitor, Ro 41-0960 reversed the 4-OHE 2 -mediated decrease of cell number suggesting this observation could be a COMTspecific effect ( Figure 2C ). As indicated in Figure 2D , 4-ME clearly caused growth inhibition of parental Caki-1 and ACHN cells. Thus, our data suggest that COMT inhibits the growth of RCC cells in the presence of 4-OHE 2 by producing 4-ME.
4-OHE 2 induces apoptotic cell death in COMT overexpressing RCC cells
Growth inhibition may result from the increase in cell cycle arrest and/or apoptotic cell death.
To further understand the growth-inhibitory effect of 4-OHE 2 , we examined cell cycle distribution and mode of cell death by flow cytometric analysis. It was observed that 4-OHE 2 treatment leads to no change in cell cycle progression (data not shown). In contrast, the apoptotic cell fractions, which were stained with Annexin V-FITC only (early apoptotic) or both Annexin V-FITC and 7-amino-actinomycin D (late apoptotic), were significantly increased in 4-OHE 2 treated cells ( Figure 3A and B) . Ro 41-0960 reduced the 4-OHE 2 -mediated apoptotic cell death ( Figure 3B ). These results suggest that 4-OHE 2 -mediated growth inhibition results from increased apoptosis in COMT-expressing RCC cells.
4-OHE 2 upregulates GADD45a in COMT overexpressing RCC cells
To gain insight into the underlying mechanisms of the COMT-mediated growth inhibition of RCC cells, we examined changes in gene expression in Caki-1/COMT cells exposed to 4-OHE 2 using the Human Apoptosis RT 2 Profiler PCR Array containing Q-PCR primers of 84 known apoptosis-related genes. From the genes analyzed, the expression of eight genes was significantly increased and among them, GADD45a was greatest at 8.6-fold (Table I) .
To verify the array data, we performed Q-PCR assay with a different probe than the one used in the PCR array. Consistently, a robust increase of GADD45a mRNA expression was detected in both Caki-1/ COMT (7.8-fold) and ACHN/COMT cells (5.5-fold) ( Figure 4A ). Next, we explored whether the 4-OHE 2 -induced elevation in GADD45a mRNA is associated with an increase in protein level. As shown by western blotting, GADD45a protein expression was significantly increased by exposure to 4-OHE 2 in both Caki-1/COMT and ACHN/COMT cells ( Figure 4B ). Furthermore, 4-ME promoted GADD45a protein expression in parental Caki-1 and ACHN cells ( Figure 4C ). Since GADD45a was the most dramatically regulated gene among those examined, we hypothesized that GADD45a may play a pivotal role in growth inhibition by 4-OHE 2 in COMT overexpressing RCC cells.
Inhibition of GADD45a prevents apoptotic cell death by 4-OHE 2 in COMT overexpressing RCC cells
To determine whether GADD45a is a key effector in the 4-OHE 2 metabolism-mediated downstream signaling pathways, we measured apoptotic cell death by exploiting GADD45a siRNA to selectively knock down GADD45a in RCC cells. We first confirmed the ability of siGADD45a duplexes to suppress endogenous GADD45a level. Administration of GADD45a siRNA to COMT overexpressing RCC cells decreased both basal mRNA (data not shown) and protein ( Figure 5A ) expression. In the presence of control siRNA, 16-21% of cells underwent apoptosis in response to 4-OHE 2 . COMT overexpressing RCC cells treated with GADD45a siRNA, in contrast, were refractory to the proapoptotic activity of 4-OHE 2 ( Figure 5A ). Furthermore, we examined the possible role of GADD45a in the antiproliferative effect of 4-ME. GADD45a siRNA efficiently inhibited both basal GADD45a mRNA (data not shown) and protein ( Figure 5B ) expression in parental Caki-1 and ACHN cells. Silencing COMT inhibits human RCC of the GADD45a gene by siRNA also prevented 4-ME-induced apoptosis ( Figure 5B ). These results demonstrate that GADD45a is an essential mediator of 4-OHE 2 -induced apoptosis in COMT overexpressing RCC cells.
Discussion
It has been suggested that reduced enzymatic activity and altered expression of COMT are associated with the development and progression of various types of cancers. A polymorphic variant of COMT that may affect gene expression as a result of a change in RNA structure and thus, translation efficiency, could potentially lead to human RCC (22) . Therefore, in the present study, we determined the expression level and functional significance of COMT in human RCC.
In the human kidney, most of the COMT expression is found in the cytoplasm of epithelial cells of convoluted tubules, in particular, of the juxtamedullary cortex region, which corresponds to findings in rat and hamster (24, 28) . A marked decrease of COMT expression in human RCC tissues and cells is also consistent with other studies observing no COMT immunoreactivity in hamster RCC (29, 30) . Although the mechanisms causing the decrease in COMT gene expression are not fully understood, there are three possibilities: First, estrogen regulates COMT expression and activity (30, 31) and chronic exposure to estrogen at high doses leads to estrogen-associated cancer. Therefore, it is conceivable that high levels of estrogen in cancer patients may lead to COMT downregulation; second, there are many polymorphisms that have been identified in the COMT gene. COMT polymorphic variants in the coding region have been shown to result in either reduced enzyme activity or structural changes in mRNA, and as a result, cause altered protein expression (32, 33) . COMT polymorphism have been shown to correlate with RCC (22) and thus, variants may lead to lower expression in cancer; and third, aberrant methylation of the promoter region of genes is one of the major mechanisms for the loss of tumor suppressor gene function in human cancer (34) . According to Sasaki et al. (35) , COMT expression can be inactivated by CpG hypermethylation. Thus, analysis of the methylation status of the COMT promoter in RCC may give insight into the regulatory mechanism of COMT expression. However, despite these possibilities, the mechanisms behind the decreased levels of COMT in renal cancers are not clear and remain to be further defined.
In this study, we found that MB-COMT is predominantly expressed in RCC cell lines. This is also observed in a human cervical cancer (HeLa), malignant melanoma (SK-MEL-5), colon adenocarcinoma (Colo 320DM), neuroblastoma (IMR-32) and bone marrow (KG-1) cell lines (25) . Whether this selective expression pattern is the case for RCC tissues is unknown since the antibody we used in the immunohistochemistry study detects both MB-and S-COMT, and high quality of antibodies which can specifically detect one of the isoforms are not commercially available.
It has been suggested that COMT may contribute to prevent the development of cancers in two ways. First, it reduces the level of 4-OHE 2 , thereby lowering the potential for genomic damage through DNA adduct formation or through oxygen radicals arising from quinone-semiquinone redox cycling of catechol estrogen (15, 16) . Second, it converts 2-OHE 2 to 2-ME, which has antiproliferative, antiangiogenic and proapoptotic effects on multiple types of cancer (17) . Unlike 2-ME, the biological function of 4-ME is largely unknown. Since it has little effect in experimental conditions where 2-ME is highly effective, 4-ME is believed to be primarily an end product of the COMT-mediated clearing mechanism of 4-OHE 2 . However, in studies by Zhu et al. (36) and Dawling et al. (37) , 4-ME serves as a substrate for 4-OHE 2 formation by demethylation catalyzed by CYP1B1. Moreover, Cheng et al. (38) showed that 4-ME can inhibit growth of human lung epithelial cells by inducing oxidative DNA damage via reactive oxygen species production.
Aside from the functions previously reported, the roles of 4-ME as an effective inhibitor of proliferation and an initiator of apoptosis in human RCC are newly discovered. Treatment of renal cancer cells with 4-ME fully mimicked the growth inhibition by GADD45a upregulation which were mediated by 4-OHE 2 in COMT overexpressing cells. In contrast to our results, no inhibitory effect of 4-ME on proliferation of endometrial, breast and cervical cancer cells has been reported (26, 27) . This discrepancy may arise from the different concentrations of 4-ME used for experiments. Kato et al. and Gong et al. measured cell viability at concentrations of 2 and 20 lM, respectively, whereas we used 50 lM based on the results with different dosages and indeed, cytotoxicity was observed at 30 lM of 4-ME in RCC cells (Supplementary Figure 1 is available at Carcinogenesis Online). With respect to 2-ME, the sensitivity of RCC cells is also different from that of endometrial cancer cells. While 5 lM 2-ME was capable of reducing viability of endometrial cancer cells by 30-35% (26,27) , 70-75% reduction was observed in RCC cells (Chang,I. and Tanaka,Y, unpublished results). These data suggest that the growth-inhibitory effect of 4-ME might be cell-type specific or require higher concentrations in RCC cells compared with endometrial cancer cells. In summary, our study have shown that COMT expression is decreased in human RCC and that ectopic COMT expression in response to 4-OHE 2 showed in vitro tumor suppressive abilities by affecting proliferation and apoptosis. A further study showed that the antiproliferative effect of COMT is due to 4-ME production and the resultant induction of GADD45a. Our study demonstrates the importance of COMT in the prevention of RCC development and provides support for COMT as a promising biomarker candidate and gene therapy targets for treating human RCC.
Supplementary material
Supplementary Figure 1 can be found at http://carcin.oxfordjournals. org/.
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